Ginsburg R, Bristow M R, Kantrowitz N, Baim D S, Harrison D C
Am Heart J. 1981 Nov;102(5):819-22. doi: 10.1016/0002-8703(81)90030-2.
Twelve patients with nonexertional chest pain and nonobstructive fixed coronary disease (less than 50% luminal diameter narrowing) were given histamine to investigate the potential role (coronary artery H1 receptor agonism) of the endogenous agent in producing coronary artery spasm (CAS). Histamine, at intravenous dose of 0.5 to 1.0 microgram/kg/min, provoked CAS in four patients. In six patients neither histamine nor ergonovine provoked spasm, and these patients were considered by chronic follow-up evaluation to have noncardiac etiology for their chest pain syndrome. In one patient CAS was provoked with ergonovine but not by histamine, and one ergonovine-positive patient had an equivocally positive histamine result. Pretreatment with cimetidine (H2 receptor antagonism) was necessary to avoid unpleasant side effects of histamine. Thus these observations indicate that histamine should be included among the specific agents capable of inducing CAS and provide new insight concerning the mechanism(s) causing variant angina pectoris.
对12例非劳力性胸痛且冠状动脉无阻塞性固定病变(管腔直径狭窄小于50%)的患者给予组胺,以研究内源性物质(冠状动脉H1受体激动)在引发冠状动脉痉挛(CAS)中的潜在作用。静脉注射剂量为0.5至1.0微克/千克/分钟的组胺,使4例患者引发了CAS。6例患者组胺和麦角新碱均未引发痉挛,通过长期随访评估,这些患者胸痛综合征的病因被认为是非心脏性的。1例患者麦角新碱引发了CAS,但组胺未引发,1例麦角新碱阳性患者组胺结果呈可疑阳性。为避免组胺产生不适的副作用,需要用西咪替丁(H2受体拮抗)进行预处理。因此,这些观察结果表明,组胺应被列入能够诱发CAS的特定药物之中,并为变异型心绞痛的发病机制提供了新的见解。